Heteroaryl compounds for kinase inhibition
US11958850B2 · kind B2 · utility
0Cited by
2References
22Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 31, 2021 |
| Grant date | Apr 16, 2024 |
| Priority date | — |
| Expiry date | Aug 31, 2041 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07F9/65583
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
Compounds and pharmaceutical compositions that modulate kinase activity, including mutant EGFR and mutant HER2 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including mutant EGFR and mutant HER2 activity, are described herein.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.